Control of cell migration and inflammatory mediators production by CORM-2 in osteoarthritic synoviocytes

Area of Science:

• Biomedical Science
• Molecular Biology
• Immunology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by inflamed synovial cells releasing mediators that damage articular tissues.
• Previous research indicates carbon monoxide-releasing molecules (CO-RMs) possess anti-inflammatory properties in OA models.
• This study investigates CO-releasing molecule-2 (CORM-2) effects on human OA synoviocyte migration and mediator production.

Purpose of the Study:

• To evaluate the impact of CORM-2 on human OA synoviocyte migration.
• To assess CORM-2's ability to modulate the production of inflammatory and catabolic mediators in OA.
• To explore the molecular mechanisms underlying CORM-2's effects on OA synoviocytes.

Main Methods:

• Human OA synoviocytes were stimulated with interleukin-1β (IL-1β) with or without CORM-2.
• Cell migration was assessed using transwell assays.
• Gene and protein expression of inflammatory mediators (IL-8, CCL2, CCL20, MMP-1, MMP-3) and signaling pathways (ERK1/2, JNK1/2, p38, NF-κB, AP-1) were analyzed via qPCR, Western Blot, and ELISA.

Main Results:

• CORM-2 significantly reduced OA synoviocyte proliferation and migration.
• CORM-2 decreased the expression and production of key inflammatory chemokines (IL-8, CCL2, CCL20) and matrix metalloproteinases (MMP-1, MMP-3).
• CORM-2 inhibited the phosphorylation of key signaling kinases (ERK1/2, JNK1/2, p38) and the activation of transcription factors NF-κB and AP-1.

Conclusions:

• CORM-2 effectively down-regulates critical synoviocyte functions involved in OA synovitis and joint degradation.
• These findings suggest CORM-2 and similar agents hold therapeutic potential for inflammatory and degenerative joint diseases.
• Targeting synoviocyte activity with CO-RMs represents a promising strategy for OA treatment.